The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023

Biden doubles down on drug pricing in 2024 budget — but boosts R&D

The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

By Karissa Waddick • March 13, 2023

Across therapy areas, GoodRx’s POS rebates improve access and affordability for cash-paying patients

Across therapy areas, GoodRx Assist is a proven point-of-sale rebate program for cash-paying patients.

March 13, 2023

IQVIA’s OG of data analytics on the latest clinical trial trends

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

By Taren Grom • March 10, 2023

Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

By Michael Gibney • March 7, 2023

FDA ups generics and biosimilar approvals for a shot at lower drug costs

As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

By Karissa Waddick • March 6, 2023

Why layoffs are not the answer to biopharma’s troubled market

As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

By Kelly Bilodeau • March 6, 2023

Biosimilar insights to help marketers navigate the year ahead

Bracing for biosimilars? Learn how biosimilar launches differ from traditional biologics.

March 6, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

Woman of the Week: Denali Therapeutics’ Cindy Dunkle

As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

By Taren Grom • March 1, 2023

Do R&D costs justify the price of drugs? Nope, new study says

A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

By Alexandra Pecci • March 1, 2023

Reata’s stock plummets amid sudden FDA neuro office shakeup

The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

By Karissa Waddick • Feb. 28, 2023

As clinical trials face a hiring crunch, here’s how research organizations can pivot

Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

By Kelly Bilodeau • Feb. 27, 2023

Why FDA’s approach to orphan drug exclusivity is ripe for more legal challenges

Despite a court ruling, the FDA is sticking to its narrow orphan drug exclusivity approach. But confusion remains over the policy’s future. 

By Karissa Waddick • Feb. 23, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023

Why the pharma industry is digging deep in rare disease

The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.

By Michael Gibney • Feb. 21, 2023

Despite rare disease market growth, pharma leaders see development obstacles ahead

Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.

By Karissa Waddick • Feb. 17, 2023

Marking one year as FDA commissioner, Califf lays out vision for agency’s future

Califf outlined hopes to address advisory committees, drug pricing, digital health and more.

By Karissa Waddick • Feb. 16, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023